Subas Chandra Dinda

Prof. Dr. Subas Chandra Dinda

School of Pharmacy, The Neotia University, Diamond Harbour, India
orcid
Professor and Dean, School of Pharmacy, The Neotia Universit...

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
SCSantanu Chakraborty
Santanu Chakraborty
MKMadhusmruti Khandai
Madhusmruti Khandai
ASAnuradha Sharma
Anuradha Sharma
NKNazia Khanam
Nazia Khanam
CPCh. Patra
Ch. Patra
KSKalyan Sen
Kalyan Sen
Preparation,in vitroandin vivoevaluation of algino-pectinate bioadhesive microspheres: An investigation of the effects of polymers using multiple comparison analysis: Ionotropic gelation was used to entrap aceclofenac into algino-pectinate bioadhesive microspheres as a potential drug carrier for the oral delivery of this anti-inflammatory drug. Microspheres were investigatedin vitrofor possible sustained drug release and their usein vivoas a gastroprotective system for aceclofenac. Polymer concentration and polymer/drug ratio were analyzed for their influence on microsphere properties. The microspheres exhibited good bioadhesive property and showed high drug entrapment efficiency. Drug release profiles exhibited faster release of aceclofenac from alginate microspheres whereas algino-pectinate microspheres showed prolonged release. Dunnet's multiple comparison analysis suggested a significant difference in percent inhibition of paw edema when the optimized formulation was compared to pure drug. It was concluded that the algino-pectinate bioadhesive formulations exhibit promising properties of a sustained release form for aceclofenac and that they provide distinct tissue protection in the stomach.

16 April 2024 in Phytomedicine
Verified
Journal Article
Closed access
SRSukanta Roy
Sukanta Roy
AGArya Ghosh
Arya Ghosh
AMAnkit Majie
Ankit Majie
VKVarnita Karmakar
Varnita Karmakar
SDSourav Das
Sourav Das
BGBapi Gorain
Bapi Gorain

8 June 2014 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
Subas Chandra DindaSubas Chandra Dinda
Subas Chandra Dinda
GPGurudutta Pattnaik
Gurudutta Pattnaik
Blood brain barrier (BBB) found to act as rate limiting factor in drug delivery to brain in combating the central nervous system (CNS) disorders. Such limiting physiological factors include the reticuloendothelial system and protein opsonization, which present across BBB, play major role in reducing the passage of drug. Several approaches employed to improve the drug delivery across the BBB. Nanoparticles (NP) are the solid colloidal particle ranges from 1 to 1000nm in size utilized as career for drug delivery. At present NPs are found to play a significant advantage over the other methods of available drug delivery systems to deliver the drug across the BBB. Nanoparticles may be because of its size and functionalization characteristics able to penetrate and facilitate the drug delivery through the barrier. There are number of mechanisms and strategies found to be involved in this process, which are based on the type of nanomaterials used and its combination with therapeutic agents, such materials include liposomes, polymeric nanoparticles and non-viral vectors of nano-sizes for CNS gene therapy, etc. Nanotechnology is expected to reduce the need for invasive procedures for delivery of therapeutics to the CNS. Some devices such as implanted catheters and reservoirs however will still be needed to overcome the problems in effective drug delivery to the CNS. Nanomaterials are found to improve the safety and efficacy level of drug delivery devices in brain targeting. Nanoegineered devices are found to be delivering the drugs at cellular levels through nono-fluidic channels. Different drug delivery systems such as liposomes, microspheres, nanoparticles, nonogels and nonobiocapsules have been used to improve the bioavailability of the drug in the brain, but microchips and biodegradable polymeric nanoparticulate careers are found to be more effective therapeutically in treating brain tumor. The physiological approaches also utilized to improve the transcytosis capacity of specific receptors expressed across the BBB. It is found that the low density lipoproteins related protein (LPR) with engineered peptide compound (EpiC) formed the platform incorporating the Angiopep peptide as a new effective therapeutics. The current challenges are to design and develop the drug delivery careers, which must be able to deliver the drug across the BBB at a safe and effective manner. Nanoparticles are found to be effective careers in delivery of conventional drugs, recombinant proteins, vaccines as well as nucleotides. Nanoparticlulate drug delivery systems are found to be improving in the pharmacokinetic strategies of the drug molecules such as biodistribution, bioavailability and drug release characteristics in a controlled and effective manner with site specific drug delivery targeting to tissue or cell with reduction in toxic manifestation. Therefore, the use of nanotechnology in the field of pharmaceutical biotechnology helps in improving the drug delivery strategy including the kinetics and therapeutic index to solve the delivery problems of some biotech drugs including the recombinant proteins and oligonucleotides. This review is made to provide an insight to the role of nanobiotechnology in drug delivery and drug targeting to brain and its recent advances in the field of drug delivery systems.

9 June 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
GMGarima Mishra
Garima Mishra
PSPradeep Singh
Pradeep Singh
MMMulugeta Molla
Mulugeta Molla
YYYohannes Shumet Yimer
Yohannes Shumet Yimer
Subas Chandra DindaSubas Chandra Dinda
Subas Chandra Dinda
AEAmien Ewunetie
Amien Ewunetie
In the current scenario, prolonged consumption of alcohol across the globe is upsurging an appreciable number of patients with the risk of alcohol-associated liver diseases. According to the recent report, the gut-liver axis is crucial in the progression of alcohol-induced liver diseases, including steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Despite several factors associated with alcoholic liver diseases, the complexity of the gut microflora and its great interaction with the liver have become a fascinating area for researchers due to the high exposure of the liver to free radicals, bacterial endotoxins, lipopolysaccharides, inflammatory markers, etc. Undoubtedly, alcohol-induced gut microbiota imbalance stimulates dysbiosis, disrupts the intestinal barrier function, and trigger immune as well as inflammatory responses which further aggravate hepatic injury. Since currently available drugs to mitigate liver disorders have significant side effects, hence, probiotics have been widely researched to alleviate alcohol-associated liver diseases and to improve liver health. A broad range of probiotic bacteria like Lactobacillus, Bifidobacteria, Escherichia coli, Sacchromyces, and Lactococcus are used to reduce or halt the progression of alcohol-associated liver diseases. Several underlying mechanisms, including alteration of the gut microbiome, modulation of intestinal barrier function and immune response, reduction in the level of endotoxins, and bacterial translocation, have been implicated through which probiotics can effectively suppress the occurrence of alcohol-induced liver disorders. This review addresses the therapeutic applications of probiotics in the treatment of alcohol-associated liver diseases. Novel insights into the mechanisms by which probiotics prevent alcohol-associated liver diseases have also been elaborated.

18 March 2025 in Results in Chemistry
Verified
Journal Article
Open access
SDSourav Das
Sourav Das
SRSukanta Roy
Sukanta Roy
Subas Chandra DindaSubas Chandra Dinda
Subas Chandra Dinda
ABAnirbandeep Bose
Anirbandeep Bose
CMChinmaya Mahapatra
Chinmaya Mahapatra
BPBhupendra Prajapati
Bhupendra Prajapati

1 April 2013 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
JSJammula Sruti
Jammula Sruti
CPChinam Niranjan Patra
Chinam Niranjan Patra
SSSuryakanta Swain
Suryakanta Swain
KPKAHNU CHARAN PANIGRAHI
KAHNU CHARAN PANIGRAHI
APAllupati Premananda Patro
Allupati Premananda Patro
MRMuddana Eswara Bhanoji Rao
Muddana Eswara Bhanoji Rao
A combination of melt-granulated dispersion and surface adsorption techniques was used to enhance the dissolution and tableting properties of cefuroxime axetil (CA). Gelucire 50/13 was used as the melt-dispersion carrier and Sylysia 350 was used to adsorb the melt dispersion. Solubility studies showed an 8-fold increase in solubility at a ratio of 1:1.5 for CA:Gelucire 50/13. The minimum quantity of Sylysia 350 required to achieve the desired flowability and compressibility was 0.5 parts of Sylysia 350 per unit of Gelucire 50/13. Phase solubility studies showed negative ΔGtr0 values for Gelucire 50/13 at various concentrations (2–10%, w/v), indicating the spontaneous nature of solubilization. FT-IR and DSC spectra exhibited drug-excipient compatibility. Molecular modeling by a computational method employing energy minimization revealed entrapment of CA in Gelucire 50/13. The total potential energy of CA (70.562kcal/mol) was reduced to 33.578kcal/mol after solid dispersion with Gelucire 50/13. P-XRD studies indicated that the presence of Sylysia 350 is less likely to promote the reversion of the amorphous CA to a crystalline state. In vitro dissolution studies demonstrated an improved dissolution rate, and drug release at 15min (Q15min) exhibited a 15-fold improvement. The rapidly dissolving CA tablets showed improved dissolution with improved tableting properties